NEW YORK (GenomeWeb News) – Exiqon today announced it has issued a non-exclusive license to Idexx Laboratories for its LNA (locked nucleic acid) technology for veterinary disease diagnostic products.
The deal provides Exiqon with upfront and milestone payments, as well as royalty payments on global sales of products covered by the agreement. Further financial details were not disclosed.
"We are excited that the LNA technology is now being applied in veterinary diagnostic products, which emphasizes the broad applicability of the LNA technology," Lars Kongsbak, president and CEO of Exiqon, said in a statement.
The deal is part of a strategy begun a year ago by the company to license out the technology in markets that Exiqon does not plan to pursue itself.